{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:10:59Z","timestamp":1777936259987,"version":"3.51.4"},"reference-count":33,"publisher":"Japan Atherosclerosis Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,5,1]]},"DOI":"10.5551\/jat.66073","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T22:08:29Z","timestamp":1769983709000},"page":"655-664","source":"Crossref","is-referenced-by-count":0,"title":["An Elevated Serum Apolipoprotein C-III Concentration is Associated with the Risk of Coronary Heart Disease in a Japanese General Population. The Hidaka Cohort Study"],"prefix":"10.5551","volume":"33","author":[{"given":"Yoshio","family":"Fujioka","sequence":"first","affiliation":[{"name":"Division of Clinical Nutrition, Faculty of Nutrition, Kobe Gakuin University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Toyooka Hospital Hidaka Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Tsujino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmacy, Hyogo Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Ishida","sequence":"additional","affiliation":[{"name":"Division of Practical Nursing, Kobe University Graduate School of Health Sciences"},{"name":"Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine"},{"name":"Department of Cardiology, Kakogawa City Hospital Organization, Kakogawa Central City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol, 2013; 61: 427-436","DOI":"10.1016\/j.jacc.2012.08.1026"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nordestgaad BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease. New insights from epidemiology, genetics, and biology. Circ Res, 2016; 118: 547-563","DOI":"10.1161\/CIRCRESAHA.115.306249"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin RA, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskine M-R, Tokg\u00f6zo\u011flu LS, Tybjaerg-Hansen A, Stock JK, Catapano AL. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J, 2021; 42: 4791-4806","DOI":"10.1093\/eurheartj\/ehab551"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Jebari-Benslaiman S, Galicia-Garc\u00eda U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, Benito-Vicente A, and Mart\u00edn C. Pathophysiology of atherosclerosis. Int J Mol Sci, 2022; 23: 3346","DOI":"10.3390\/ijms23063346"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Doi T, Langsted A, Nordestgaard BG. Lipoproteins, cholesterol, and atherosclerotic cardiovascular disease in East Asian and Europeans. J Atheroscler Thromb, 2023; 30: 1525-1546","DOI":"10.5551\/jat.RV22013"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherosclerosis. J Atheroscler Thromb, 2009; 16: 145-154","DOI":"10.5551\/jat.E598"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Mehta A, Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease. Nat Rev Cardiol, 2022; 19: 168-179","DOI":"10.1038\/s41569-021-00613-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) D\u2019Erasmo L , Di Costanzo A , Gallo A , Bruckert E, Arca M. ApoCIII: a multifaceted protein in cardiometabolic disease. Metabolism, 2020; 113: 154395","DOI":"10.1016\/j.metabol.2020.154395"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) De la Parra Soto, Guti\u00e9rrez-Uribe JA, Sharma A, Ram\u00edrez-Jim\u00e9nez AK. Is Apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies. Nutr Metab Cardiovasc Dis, 2022; 32: 295-308","DOI":"10.1016\/j.numecd.2021.09.035"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Packard CJ, Pirillo A, Tsimikas S, Ference BA, Catapano AL. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance. Cardiovasc Res, 2023; 119: 2843","DOI":"10.1093\/cvr\/cvad177"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Scheffer PG, Teerlink T, Dekker JM, Bos G, Nijpels G, Diamant M, Kostense PJ, Stehouwer CDA, Heine RJ. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: The Hoorn Study. Clin Chem, 2008; 54: 1325-1330","DOI":"10.1373\/clinchem.2008.103234"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Wyler von Ballmoos MC, Haring B, Sacks FM. The risk of cardiovascular events with increased apolipoprotein CIII: a systemic review and meta-analysis. J Clin Lipidol, 2015; 9: 498-510","DOI":"10.1016\/j.jacl.2015.05.002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hussain A, Sun C, Selvin E, Nambi V, Coresh J, Jia X, Balllantyne CM, Hoogeveen RC. Triglyceride-rich lipoproteins, apolipoprotein C-III. Angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. Eur J Cardiol, 2022; 29: e53-e64","DOI":"10.1093\/eurjpc\/zwaa152"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tanaka S, Miki T, Sha S, Hirata K, Ishikawa Y, Yokoyama M. Serum levels of Thiobarbituric acid-reactive substances are associated with risk of coronary heart disease. J Atheroscler Thromb, 2011; 18: 584-591","DOI":"10.5551\/jat.6585"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tanaka S, Yasuda T, Ishida T, Fujioka Y, Tsujino T, Miki T, Hirata K. Increased serum cholesterol esterification rates predict coronary heart disease and sudden death in a general population. Arterioscler Thromb Vasc Biol, 2013; 33: 1098-1104","DOI":"10.1161\/ATVBAHA.113.301297"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Tanaka S-I, Fujioka Y, Tsujino T, Ishida T, Hirata K-I. Impact of serum cholesterol esterification rates on the development of diabetes mellitus in a general population. Lipids Health Dis, 2018; 17: 180","DOI":"10.1186\/s12944-018-0822-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Tanaka SI, Fujioka Y, Tsujino T, Ishida T, Hirata KI. Association between urinary N-acetyl-\u03b2-glucosaminidase activity-urinary creatinine concentration ratio and risk of disability and all-cause mortality. PLoS One, 2022; 17: e0265637","DOI":"10.1371\/journal.pone.0265637"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation, 1994; 90: 583-612","DOI":"10.1161\/01.CIR.90.1.583"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Arvantis M, Lowenstein CJ. Dyslipidemia. Ann Intern Med, 2023; 176: ITC81-ITC96","DOI":"10.7326\/AITC202306200"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Masuda D, Yamashita S. Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb, 2017; 24: 95-109","DOI":"10.5551\/jat.RV16003"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Nagasawa SY, Okamura T, Iso H, Tamakoshi A, Yamada M, Watanabe M, Murakami Y, Miura K, Ueshima H; Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH-JAPAN) Research Group. Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65 594 individuals from 10 cohort studies in Japan. J Am Heart Assoc, 2012; 1: e001974","DOI":"10.1161\/JAHA.112.001974"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, Kondo T, Watanabe Y, Koizumi A, Inaba Y, Tamakoshi A, JACC Study Group. Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: The JACC study. Atherosclerosis, 2007; 194: 415-420","DOI":"10.1016\/j.atherosclerosis.2006.08.022"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sekimoto T, Koba S, Mori H, Sakai R, Arai T, Yokota Y, Sato S, Tanaka H, Masaki R, Oishi Y, Ogura K, Arai K, Nomura K, Kosaki R, Sakai K, Tsujita H, Kondo S, Tsukamoto S, Tsunoda F, Shoji M, Matsumoto H, Hamazaki Y, Shinke T. Small dense Low-density lipoprotein cholesterol: a residual risk for rapid progression on non-culprit coronary lesion in patients with acute coronary syndrome. J Atheroscler Thromb, 2021; 28: 1161-1174","DOI":"10.5551\/jat.60152"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kitahara S, Kataoka Y, Nicholls SJ, Funahashi S, Nakatsuka K, Nishimura K, Makino H, Matsubara M, Matsuo M, Omura-Ohara Y, Koezuka R, Tochiya M, Tamanaha T, Tomita T, Honda-Kohmo K, Noguchi M, Murai K, Iwai T, Sawada K, Matama H, Honda S, Fujino M, Yoneda S, Takagi K, Otsuka F, Asaumi Y, Hosoda K, Yasuda S, Noguchi T. Apolipoprotein CIII in station-treated type 2 diabetic patients: its implications for plaque progression and instability: the pre-specified analysis from the OPTIMAL randomized controlled trial. Atherosclerosis, 2025; 409: 120470","DOI":"10.1016\/j.atherosclerosis.2025.120470"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Fredenrich A, Giroux L-M, Tremblay M, Krimbou L, Davignon J, Cohn JS. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J Lipid Res, 1997; 38: 1421-1432","DOI":"10.1016\/S0022-2275(20)37424-1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Olin-Lewis K, Krauss RM, La Belle M, Blanche PJ, Barrett PHR, Wight TN, Chait A. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. J Lipid Res, 2002; 43: 1969-1977","DOI":"10.1194\/jlr.M200322-JLR200"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Zewinger S, Reiser J, Jankowski V, Alansary D, Halm E, Triem S, Klug M, Schunk SJ, Schmit D, Kramann R, K\u00f6rbel C, Ampofo E, Laschke MW, Selejan S-R, Paschen A, Herter T, Schuster S, Silbernagel G, Sester M, Sester U, A\u00dfmann G, Bals R, Kostner G, Jahnen-Dechent W, Menger MD, Rohrer L, M\u00e4rz W, B\u00f6hm M, Jankowski J, Kopf M, Latz E, Niemeyer BA, Fliser D, Laufs U, Speer T. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol, 2020; 21: 30-41","DOI":"10.1038\/s41590-019-0548-1"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hsu C-C, Shao B, Kanter JE, He Y, Vaisar T, Witztum JL, Snell-Bergeon J, Mclnnes G, Bruse S, Gottesman O, Mullick AE, Bornfeldt KE. Apolipoprotein C3 induces inflammasome activation only in its de-lipidated form. Nat Immunol, 2023; 24: 408-411","DOI":"10.1038\/s41590-023-01423-2"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Bruckert E. Volanesorsen and triglyceride levels in familial vhylomicronemia syndrome. New Engl J Med, 2019; 381: 531-542","DOI":"10.1056\/NEJMoa1715944"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, Soran H, Prohaska TA, Xia S, Ginsberg HN, Witztum JL, Tsimikas S. Balance Investigators: Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. New Engl J Med, 2019; 390: 1781-1792","DOI":"10.1056\/NEJMoa2400201"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D. Plozasiran, an RNA interference agent targeting apoC-III, for mixed hyperlipidemia. New Engl J Med, 2024; 391: 899-912","DOI":"10.1056\/NEJMoa2404143"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Rai H, Sinha N, Finn J, Agrawal S, Mastana S. Association of serum lipids and coronary artery disease with polymorphisms in the apolipoprotein AI-CIII-AIV gene cluster. Cognet Medicine, 2016; 3: 1266789","DOI":"10.1080\/2331205X.2016.1266789"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Sun M, Chen L, Liu H, Ma L, Wang T, Liu Y. Association of the S2 allele of the SstI polymorphism in the apoC3 gene with plasma apoCIII interacts with unfavorable lipid profiles to contribute to atherosclerosis in the Li ethnic group in China. Lipid Health Dis, 2017; 16: 220","DOI":"10.1186\/s12944-017-0614-3"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/5\/33_66073\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:25:05Z","timestamp":1777692305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/5\/33_66073\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.66073","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"66073"}}